X-linked retinoschisis maculopathy treated with topical dorzolamide, and relationship to genotype

Eye

Volumn 25, Issue 7, 2011, Pages 922-928

  Khandhadia, S ^a   Trump, D ^b   Menon, G ^c   Lotery, A J ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

dorzolamide; macular oedema; X linked retinoschisis

Indexed keywords

DORZOLAMIDE;

ADOLESCENT; ARTICLE; CASE REPORT; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULOPATHY; RETINOSCHISIS; RETINOSCHISIS GENE; SCHOOL CHILD; STUDENT T TEST; VISUAL ACUITY; X CHROMOSOME LINKED DISORDER;

EID: 79960439738     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.91     Document Type: Article

References (35)

1. de la Chapelle A, Alitalo T, Forsius H. X-linked juvenile retinoschisis. In: Wright A, Jay B (eds). Molecular Genetics of Inherited Eye Disorders, 1st edn., Harwood Academic Publishers: Switzerland, 1994, pp 339-357.
2. Sikkink SK, Biswas S, Parry NR, Stanga PE, Trump D. X-linked retinoschisis: an update. J Med Genet 2007; 44: 225-232. (Pubitemid 46596435)
3. Iannaccone A, Fung KH, Eyestone ME, Stone EM. Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide. Am J Ophthalmol 2009; 147: 307-312.
4. Forsius H, Krause U, Helve J, Vuopala V, Mustonen E, Vainio-Mattila B et al. Visual acuity in 183 cases of X-chromosomal retinoschisis. Can J Ophthalmol 1973; 8: 385-393.
5. Grayson C, Reid SN, Ellis JA, Rutherford A, Sowden JC, Yates JR et al. Retinoschisin, the X-linked retinoschisis protein, is a secreted photoreceptor protein, and is expressed and released by Weri-Rb1 cells. Hum Mol Genet 2000; 9: 1873-1879. (Pubitemid 30608620)
6. Zeng Y, Takada Y, Kjellstrom S, Hiriyanna K, Tanikawa A, Wawrousek E et al. RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis. Invest Ophthalmol Vis Sci 2004; 45: 3279-3285. (Pubitemid 39121867)
7. Ewing CC, Ives EJ. Juvenile hereditary retinoschisis. Trans Ophthalmol Soc UK 1970; 89: 29-39.
8. Ando A, Takahashi K, Sho K, Matsushima M, Okamura A, Uyama M. Histopathological findings of X-linked retinoschisis with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 2000; 238: 1-7. (Pubitemid 30160494)
9. Sarin LK, Green WR, Dailey EG. Juvenile retinoschisis. Congenital vascular veils and hereditary retinoschisis. Am J Ophthalmol 1964; 57: 793-796.
10. Sauer CG, Gehrig A, Warneke-Wittstock R, Marquardt A, Ewing CC, Gibson A et al. Positional cloning of the gene associated with X-linked juvenile retinoschisis. Nat Genet 1997; 17: 164-170. (Pubitemid 27425948)
11. Wu WW, Molday RS. Defective discoidin domain structure, subunit assembly, and endoplasmic reticulum processing of retinoschisin are primary mechanisms responsible for Xlinked retinoschisis. J Biol Chem 2003; 278: 28139-28146. (Pubitemid 36900012)
12. Wu WW, Wong JP, Kast J, Molday RS. RS1, a discoidin domain-containing retinal cell adhesion protein associated with X-linked retinoschisis, exists as a novel disulfidelinked octamer. J Biol Chem 2005; 280: 10721-10730. (Pubitemid 40395934)
13. Manschot WA. Pathology of hereditary juvenile retinoschisis. Arch Ophthalmol 1972; 88: 131-138.
14. Yanoff M, Kertesz RE, Zimmerman LE. Histopathology of juvenile retinoschisis. Arch Ophthalmol 1968; 79: 49-53.
15. Brucker AJ, Spaide RF, Gross N, Klancnik J, Noble K. Optical coherence tomography of X-linked retinoschisis. Retina 2004; 24: 151-152. (Pubitemid 38240854)
16. Ozdemir H, Karacorlu S, Karacorlu M. Optical coherence tomography findings in familial foveal retinoschisis. Am J Ophthalmol 2004; 137: 179-181. (Pubitemid 38045209)
17. Wang T, Waters CT, Rothman AM, Jakins TJ, Romisch K, Trump D. Intracellular retention of mutant retinoschisin is the pathological mechanism underlying X-linked retinoschisis. Hum Mol Genet 2002; 11: 3097-3105. (Pubitemid 35414823)
18. Jablonski MM, Dalke C,Wang X, Lu L, Manly KF, Pretsch W et al. An ENU-induced mutation in Rs1h causes disruption of retinal structure and function. Mol Vis 2005; 11: 569-581. (Pubitemid 41410219)
19. Weber BH, Schrewe H, Molday LL, Gehrig A, White KL, Seeliger MW et al. Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure. Proc Natl Acad Sci USA 2002; 99: 6222-6227. (Pubitemid 34493293)
20. Deutman A, Hoyng C, van Lith-Verhoeven J. Macular dystrophies. In: Ryan S, Hinton D, Schachat A (eds). Retina, 4th edn. Elsevier/Mosby: Philadelphia, PA, 2006, pp 1165.
21. Apushkin MA, Fishman GA. Use of dorzolamide for patients with X-linked retinoschisis. Retina 2006; 26: 741-745. (Pubitemid 44386094)
22. Ghajarnia M, Gorin MB. Acetazolamide in the treatment of X-linked retinoschisis maculopathy. Arch Ophthalmol 2007; 125: 571-573. (Pubitemid 46596736)
23. Walia S, Fishman GA, Molday RS, Dyka FM, Kumar NM, Ehlinger MA et al. Relation of response to treatment with dorzolamide in X-linked retinoschisis to the mechanism of functional loss in retinoschisin. Am J Ophthalmol 2009; 147: 111-115.
24. Genead MA, Fishman GA, Walia S. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis. Arch Ophthalmol 2010; 128: 190-197.
25. Leung CK, Cheung CY, Weinreb RN, Lee G, Lin D, Pang CP et al. Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 2008; 49: 4893-4897.
26. Grover S, Fishman GA, Gilbert LD, Anderson RJ. Reproducibility of visual acuity measurements in patients with retinitis pigmentosa. Retina 1997; 17: 33-37. (Pubitemid 27091647)
27. George ND, Yates JR, Bradshaw K, Moore AT. Infantile presentation of X linked retinoschisis. Br J Ophthalmol 1995; 79: 653-657.
28. Joint Formulary Committee. British National Formulary, ed. British Medical Association and Royal Pharmaceutical Society of Great Britain: London, 2010. www.bnf.org/bnf. BNF 56.
29. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol 2000; 44(Suppl 2): S141-S145.
30. Stewart WC, Day DG, Stewart JA, Holmes KT, Jenkins JN. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye 2004; 18: 905-910. (Pubitemid 39328328)
31. Marmor MF, Abdul-Rahim AS, Cohen DS. The effect of metabolic inhibitors on retinal adhesion and subretinal fluid resorption. Invest Ophthalmol Vis Sci 1980; 19: 893-903. (Pubitemid 11041989)
32. Marmor MF, Maack T. Enhancement of retinal adhesion and subretinal fluid resorption by acetazolamide. Invest Ophthalmol Vis Sci 1982; 23: 121-124. (Pubitemid 12089690)
33. Wolfensberger TJ, Chiang RK, Takeuchi A, Marmor MF. Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 2000; 238: 76-80. (Pubitemid 30160506)
34. Kita M, Marmor MF. Effects on retinal adhesive force in vivo of metabolically active agents in the subretinal space. Invest Ophthalmol Vis Sci 1992; 33: 1883-1887.
35. Wang T, Zhou A, Waters CT, OConnor E, Read RJ, Trump D. Molecular pathology of X linked retinoschisis: mutations interfere with retinoschisin secretion and oligomerisation. Br J Ophthalmol 2006; 90: 81-86. (Pubitemid 43029902)